Assessment of SpondyloArthritis International Society

UCB touts positive phase III Cimzia results

Monday, April 16, 2012

UCB reported positive top-line results from a phase III study designed to evaluate the efficacy and safety of Cimzia (certolizumab pegol) in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases which includes ankylosing spondylitis (AS).

[Read More]